Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

227

Participants

Timeline

Start Date

November 24, 1997

Primary Completion Date

May 1, 2002

Study Completion Date

February 10, 2009

Conditions
PainProstate CancerQuality of Life
Interventions
DRUG

clodronate disodium

DRUG

mitoxantrone hydrochloride

DRUG

prednisone

PROCEDURE

quality-of-life assessment

Trial Locations (21)

T2N 4N2

Tom Baker Cancer Center - Calgary, Calgary

V2A 3G6

Penticton Regional Hospital, Penticton

V3V 1Z2

British Columbia Cancer Agency - Fraser Valley Cancer Centre, Surrey

V5Z 4E6

B.C. Cancer Agency, Vancouver

E2L 4L2

Saint John Regional Hospital, Saint John

A1B 3V6

Newfoundland Cancer Treatment and Research Foundation, St. John's

B3H 1V7

Nova Scotia Cancer Centre, Halifax

L8V 5C2

Cancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton

K7L 5P9

Kingston Regional Cancer Centre, Kingston

N6A 4L6

Cancer Care Ontario-London Regional Cancer Centre, London

L5B 1B8

Trillium Health Centre, Mississauga

K1H 8L6

Ottawa Regional Cancer Center - General Division, Ottawa

K9H 7B6

Peterborough Oncology Clinic, Peterborough

L2R 5K3

Hotel Dieu Hospital - St. Catharines, St. Catharines

P7A 7T1

Northwestern Ontario Regional Cancer Centre, Thunder Bay, Thunder Bay

M4N 3M5

Toronto Sunnybrook Regional Cancer Centre, Toronto

M5G 2M9

Princess Margaret Hospital, Toronto

M9N 1N8

Humber River Regional Hospital, Weston

N8W 2X3

Cancer Care Ontario - Windsor Regional Cancer Centre, Windsor

C1A 8T5

Queen Elizabeth Hospital, PEI, Charlottetown

H2W 1S6

McGill University Department of Oncology, Montreal

Sponsors
All Listed Sponsors
lead

NCIC Clinical Trials Group

NETWORK